NewsBenzingaMoleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia Benzinga 2026.09.29 12:47 (GMT+0) Open on Benzinga Other news Brandywine Realty Tr Q3 FFO $0.14, Inline, Sales $125.638M Beat $121.617M Estimate FS Bancorp Q3 EPS $0.63 Misses $0.98 Estimate, Sales $40.193M Beat $35.128M Estimate Oak Valley Q3 EPS $0.77 Down From $0.81 YoY, Sales $21.653M Up From $21.170M YoY Meta Platforms Says Co. Entered Into A Founder Alignment Agreement With Mark Zuckerberg First BanCorp. Announces $350M Buyback Plan Wyndham Hotels & Resorts Raises FY2026 Adj EPS Guidance from $4.71-$4.83 to $4.84-$4.92 vs $4.80 Est; Affirms FY2026 Sales Guidance of $1.480B-$1.500B vs $1.481B Est
Wyndham Hotels & Resorts Raises FY2026 Adj EPS Guidance from $4.71-$4.83 to $4.84-$4.92 vs $4.80 Est; Affirms FY2026 Sales Guidance of $1.480B-$1.500B vs $1.481B Est
